Market Overview

Biotech Bubble Valuations From Sam Islay

Related HNT
UBS Downgrades Molina Healthcare Following Q1 Miss
Benzinga's Volume Movers
Related IBB
What Pharmaceuticals Spend On Lobbying To Influence Trump
This Drug, An Alternative To Marijuana And Ketamine, Could Treat Suicidal Depression And PTSD

Editor's note: A previous version of this story said ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) was among Isaly's picks. Isaly said the company "has done great this year," but he is looking at other stocks.

OrbiMed Advisors managing partner Sam Isaly told CNBC that biotech could be volatile, however, the valuations were "sensible."

Isaly's top picks included:

Regeneron Pharmaceuticals Inc (NASDAQ: REGN)

Actelion Ltd (OTC: ALIOF)

Molina Healthcare, Inc. (NYSE: MOH)

Health Net, Inc. (NYSE: HNT)

Isaly said that the performance of the industry had been "great" over the past three to five years and that explosive growth in new products was expected to drive biotech stocks higher.

The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) had gained nearly 50 percent over the past 12 months and closed at $340.08 Wednesday, down 0.98 percent.

Latest Ratings for HNT

Nov 2015SusquehannaMaintainsNeutral
Aug 2015BMO CapitalMaintainsMarket Perform
Aug 2015BarclaysMaintainsUnderweight

View More Analyst Ratings for HNT
View the Latest Analyst Ratings

Posted-In: Orbimed Advisors Sam IsalyAnalyst Color Biotech CNBC Analyst Ratings Media General


Related Articles (HNT + ALIOF)

View Comments and Join the Discussion!